Ravi Vij
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
Year:
2025
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
Year:
2025
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank
Year:
2025
Multiple myeloma (MM) is an incurable malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune factors driving treatment response and resistance, we conducted multi-omics profiling including CD138 neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138 pos bulk RNA and whole-genome sequencing from 209 samples. Longitudinal analyses revealed that interferon gamma signaling impairs T cell memory after autologous stem cell transplant, while naïve B cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48, p = 2.3e -4 ). At disease progression, MM cells upregulated cancer-testis antigens and immune effector genes, with concurrent B cell depletion, enrichment of myeloid-derived suppressor cell genes in monocytes, and T cell exhaustion. These findings highlight dynamic immune-tumor interactions, identifying naïve B cell reconstitution as a biomarker of durable response, and cancer-testis antigens as potential targets for high-risk disease at progression. Statement of Significance Longitudinal profiling of multiple myeloma and the immune microenvironment revealed dynamic immune-tumor interactions across the disease course. Dysfunctional CD8⁺ T cells limited memory formation post-transplant, while naïve B recovery associated with sustained treatment response. At progression, cancer-testis antigen expression associated with immunosuppression, revealing novel mechanisms of immune escape.
Year:
2025
Multiple myeloma (MM) is a highly refractory hematologic cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single-cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which were previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA sequencing reiterated top candidates, further affirming the ability of single-cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy. Significance: Single-cell transcriptomic profiling and multiomic cross-validation to uncover therapeutic targets identifies 38 myeloma marker genes, including 11 transcribing surface proteins with previously uncharacterized potential for targeted antitumor therapy.
Year:
2025
PURPOSE Financial toxicity is a contributor to the psychosocial burden of cancer care. There is no consensus measure of financial toxicity; however, recent studies have adopted the Comprehensive Score for Financial Toxicity (COST). Despite its growing popularity, data on the responsiveness to change of the COST instrument are lacking. To address this gap in the literature, we performed a sequential mixed-methods study of people with multiple myeloma. MATERIALS AND METHODS In the quantitative phase of the study, we collected COST scores at two time points approximately 8 weeks apart from 72 patients. In the qualitative phase, we conducted semistructured interviews with a subset of 12 patients who reported the largest changes in scores. The qualitative data were analyzed using a deductive coding scheme developed using the Framework Method in the context of a commonly cited conceptual model of financial toxicity. RESULTS The median absolute change in COST scores was four points (IQR, 2-6). Only 13% of the sample had the same COST scores at both assessments; 38% had an improved score and 50% had a worsened score. Only, seven of the 12 patients (58%) interviewed reported changes to one or more of the constructs in the conceptual model of financial toxicity. Most commonly, changes to out-of-pocket medical costs were reported (5/12). Changes to nonmedical expenses (n = 2) and subjective financial distress without changes to objective financial burden (n = 2) were also reported. CONCLUSION Additional research is needed to explicate changes in COST scores over time.
Year:
2024
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
Year:
2024
Multiple myeloma (MM) is a highly refractory hematological cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which are previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA-sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA-sequencing reiterated top candidates, further affirming the ability of single cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy.
Year:
2024
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
Year:
2024
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (22)
Feng Chen
Professor
Washington University in St. Louis
Shaji Kumar
Medical College of Wisconsin
Song Cao
Assistant Professor
Washington University in St. Louis
Manoj Bhasin
Director, Genomics, Proteomics, Bioinformatics and Single cell Biology
Children's Healthcare of Atlanta
Ioannis Vlachos
Broad Institute
David Avigan
Vice Chair of Oncology
Dana-Farber Cancer Institute
Mark Fiala
Assistant Professor
Washington University School of Medicine
John F. DiPersio
Director, Center for Gene and Cellular Immunotherapy
Washington University in St. Louis
Ying Zhu
Genentech Inc
Sagar Lonial
-
Scott Goldsmith
Assistant Professor
City Of Hope National Medical Center
Mehmet Samur
Senior Research Scientist
Dana-Farber Cancer Institute
Ajay K. Nooka
Professor
Emory University
Tao Liu
Sr. Staff Scientist
Pacific Northwest National Laboratory
Chia-Feng Tsai
Scorpion Therapeutics (United States)
Leah Gehrs
The University of Alabama
Li Ding
Associate Professor
Washington University in Saint Louis School of Medicine
Madhav V. Dhodapkar
-
Edgar Ernesto Gonzalez Kozlova
Assistant Professor
-
Michael Rettig
Washington University in St. Louis
Daniel W. Sherbenou
Associate Professor
University of Colorado Anschutz Medical Campus
Jonathan Keats
Director of Bioinformatics / Assistant Professor
Translational Genomics Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.